Santen Pharmaceutical Co Ltd
OTC:SNPHY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Santen Pharmaceutical Co Ltd
OTC:SNPHY
|
JP |
|
H
|
Hellenic Telecommunications Organization SA
F:OTE
|
GR |
|
Zueblin Immobilien Holding AG
F:61Z1
|
CH |
|
I
|
Internet Initiative Japan Inc
F:IIJ
|
JP |
|
S
|
Solaria Energia y Medio Ambiente SA
SWB:AOR
|
ES |
|
Mizuno Corp
F:MIZ
|
JP |
|
B
|
Booktopia Group Ltd
F:BK4
|
AU |
|
C
|
CrownHaitai Holdings Co Ltd
KRX:005745
|
KR |
|
U
|
Ucb SA
SWB:UNC
|
BE |
|
Amigo Holdings PLC
F:0VG
|
UK |
|
Circio Holding ASA
F:TA5
|
NO |
|
Noble Helium Ltd
F:GN1
|
AU |
|
M
|
Mynaric AG
XMUN:M0YN
|
DE |
|
I
|
Ivision Tech SpA
F:O42
|
IT |
Wall St Price Targets
SNPHY Price Targets Summary
Santen Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for SNPHY is 15.39 USD with a low forecast of 12.64 USD and a high forecast of 19.36 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SNPHY's stock price target?
Price Target
15.39
USD
According to Wall Street analysts, the average 1-year price target for SNPHY is 15.39 USD with a low forecast of 12.64 USD and a high forecast of 19.36 USD.
What is the Revenue forecast for Santen Pharmaceutical Co Ltd?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 3 years is 4%.
What is the Gross Profit forecast for Santen Pharmaceutical Co Ltd?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 2 years is 3%.
What is the Operating Income forecast for Santen Pharmaceutical Co Ltd?
Projected CAGR
29%
Over the last 13 years, the compound annual growth rate for Operating Income has been 5%. The projected CAGR for the next 1 year is 29%.
What is the Pre-Tax Income forecast for Santen Pharmaceutical Co Ltd?
Projected CAGR
6%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 5%. The projected CAGR for the next 2 years is 6%.
What is the Net Income forecast for Santen Pharmaceutical Co Ltd?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next 2 years is 4%.
